Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma
Leukemia · 2026
DOI: 10.1038/s41375-026-03075-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, 2026. Verfasst von Estefania Gauto Mariotti und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual, Hematopoietic Stem Cell Transplantation, Chromosome Aberrations. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Measurable residual disease (MRD) assessment has become central to risk-adapted treatment strategies in multiple myeloma, yet the prognostic value of MRD negativity following autologous stem cell transplantation (ASCT) across individual high-risk cytogenetic abnormalities (HRCAs) remains unclear. We analyzed 351 newly diagnosed patients who achieved MRD negativity (sensitivity 2.4 × 10^−6) between day 60-100 following ASCT and had baseline cytogenetic data available. Median follow-up was 50.4 months. Standard-risk cytogenetics were present in 46% ( n = 162), while 34% ( n = 118) had one HRCA and 20% ( n = 71) had ≥2 HRCAs. Despite uniform MRD negativity, several HRCAs continued to confer inferior progression-free survival (PFS). Compared with the standard-risk group (4-year PFS 84%), patients with del(17p), 1q21+, t(4;14), or MAF translocations [t(14;16)/t(14;20)] had significantly lower 4-year PFS rates: 56% (HR 2.89; p = 0.0001), 60% (HR 2.46; p = 0.0001), 43% (HR 3.50; p = 0.0001), and 58% (HR 2.51; p = 0.01), respectively. Isolated del(17p) and 1q21+ also conferred inferior PFS. The 4-year PFS was 65% for patients with one HRCA (HR 2.31; p = 0.0004) and 55% for those with ≥2 HRCAs (HR 2.75; p = 0.0001). In this large MRD-negative post-ASCT cohort, several HRCAs, including isolated HRCAs, were associated with inferior PFS, suggesting a potential persistence of high-risk biology despite early MRD negativity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology, Mayo Clinic, Rochester, MN, USA.
- Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.
- Division of Hematology, Mayo Clinic, Rochester, MN, USA. zanwar.saurabh@mayo.edu.
Zitieren
APA
Mariotti, E. G., Kumar, S., Gonsalves, W., Kapoor, P., Buadi, F., Hayman, S., Abdallah, N., Binder, M., Cook, J., Dispenzieri, A., Dingli, D., Gertz, M. A., Kourelis, T., Leung, N., Lin, Y., Siddiqui, M., Go, R., Muchtar, E., Warsame, R., …, & Zanwar, S. (2026). Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma. Leukemia. https://doi.org/10.1038/s41375-026-03075-1
Vancouver
Mariotti EG, Kumar S, Gonsalves W, Kapoor P, Buadi F, Hayman S, et al. Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma. Leukemia. 2026. doi:10.1038/s41375-026-03075-1
BibTeX
@article{Mariotti2026,
author = {Mariotti, Estefania Gauto and Kumar, Shaji and Gonsalves, Wilson and Kapoor, Prashant and Buadi, Francis and Hayman, Suzanne and Abdallah, Nadine and Binder, Moritz and Cook, Joselle and Dispenzieri, Angela and Dingli, David and Gertz, Morie A and Kourelis, Taxiarchis and Leung, Nelson and Lin, Yi and Siddiqui, Mustaqeem and Go, Ronald and Muchtar, Eli and Warsame, Rahma and Jevremovic, Dragan and Kyle, Robert A and Rajkumar, S Vincent and Zanwar, Saurabh},
title = {Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma},
journal = {Leukemia},
year = {2026},
doi = {10.1038/s41375-026-03075-1}
}
EUVIMED